Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in funding, extending its cash runway into early 2027, and has formed commercial partnerships to prepare for market launch. Despite a negative P/E ratio, Inovio received a "Buy" rating from Jefferies with a $3.00 price target. Additionally, positive Phase 3 results for VGX-3100 in China and ongoing development of treatments for rare diseases like Hemophilia A highlight the company's growth potential.